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Summary 54 
Definitive haematopoiesis in the fetal liver supports self-renewal and differentiation of 55 
haematopoietic stem cells/multipotent progenitors (HSC/MPPs) but remains poorly defined 56 
in humans.  Using single cell transcriptome profiling of ~140,000 liver and ~74,000 skin, 57 
kidney and yolk sac cells, we identify the repertoire of human blood and immune cells during 58 
development.  We infer differentiation trajectories from HSC/MPPs and evaluate the impact 59 
of tissue microenvironment on blood and immune cell development.  We reveal physiological 60 
erythropoiesis in fetal skin and the presence of mast cells, NK and ILC precursors in the yolk 61 
sac.  We demonstrate a shift in fetal liver haematopoietic composition during gestation away 62 
from being erythroid-predominant, accompanied by a parallel change in HSC/MPP 63 
differentiation potential, which we functionally validate.  Our integrated map of fetal liver 64 
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haematopoiesis provides a blueprint for the study of paediatric blood and immune disorders, 65 
and a valuable reference for harnessing the therapeutic potential of HSC/MPPs. 66 
Introduction  67 
The blood and immune systems develop during early embryogenesis.  Our understanding of 68 
this process derives from murine and in vitro model systems as human fetal tissue is scarce.  69 
While haematopoietic development is conserved across vertebrates1, important differences 70 
between mouse and human have been noted2,3.  Comprehensive interrogation of human tissue 71 
to understand the molecular and cellular landscape of early hematopoiesis has implications 72 
beyond life in utero, providing a blueprint for understanding immunodeficiencies, childhood 73 
leukemias and anaemias and generating insights into HSC/MPP propagation to inform stem-74 
cell technologies.  75 
 76 
The earliest blood and immune cells originate outside the embryo, arising from the yolk-sac 77 
between 2-3 post-conception weeks (PCW).  At 3-4 PCW, intra-embryonic progenitors from 78 
the aorta-gonad-mesonephros (AGM) develop4.  Yolk-sac and AGM progenitors colonise 79 
fetal tissues such as the liver, which remains the major organ of haematopoiesis until the mid-80 
second trimester.  Fetal bone marrow (BM) is colonised around 11 PCW and becomes the 81 
dominant site of haematopoiesis after 20 PCW in human4. Yolk sac-, AGM-, fetal liver- and 82 
BM-derived immune cells seed peripheral tissues including non-lymphoid tissues (NLT), 83 
where they undergo specific maturation programs which are both intrinsically determined and 84 
extrinsically nurtured by the tissue microenvironment5,6.  Systematic, comprehensive analysis 85 
of multiple blood and immune lineages during human development has not previously been 86 
attempted.  87 
 88 
In this study, we used single cell transcriptomics to map the molecular states of human fetal 89 
liver cells between 7-17 PCW, when the liver represents the predominant site of human fetal 90 
haematopoiesis.  We integrate imaging mass cytometry, flow cytometry and cellular91 
morphology to validate the transcriptome-based cellular profiles.  We construct the functional 92 
organisation of the developing immune network through comparative analysis of immune 93 
cells in fetal liver with those in yolk sac, and skin and kidney as representative NLT.    94 
 95 
 96 
 97 
 98 
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Results  102 
Single cell transcriptome map of fetal liver  103 
To investigate blood and immune cell development in the fetal liver, we generated single cell 104 
suspensions from embryonic and fetal livers between 6 and 17 PCW.  We FACS-isolated 105 
CD45+ and CD45- cells using adjoining gates for comprehensive capture (Figure 1a and 106 
Extended Data 9a) for single cell RNA-sequencing (scRNA-seq) (both 10x Genomics 107 
platform Smart-seq2) (Figure 1, Extended Data 4d, and Supplementary Table 1).  To allow 108 
parallel evaluation of blood and immune cell topography in NLT and the yolk sac during 109 
early development (Figure 1a) we profiled skin, kidney and yolk sac cells by FACS-isolation 110 
and 10x Genomics platform.   111 
 112 
In total, 138,575 (n = 14) liver (an additional 1,206 cells were profiled using Smart-seq2), 113 
54,690 (n = 7) skin, 9,643 kidney (n = 3) and 10,071 yolk sac (n = 3) cells passed quality 114 
control (QC) and doublet exclusion (Extended Data 1a-b, and Supplementary Table 2).  We 115 
performed graph-based Louvain clustering and derived differentially expressed genes to 116 
annotate cell clusters.  To minimize technical batch-effect while preserving biological 117 
variation due to gestational stage, we divided liver samples into four gestational stage 118 
categories and performed data integration between samples using Harmony (Extended Data 119 
1c-e).  120 
 121 
27 major cell states are present in the fetal liver (Figure 1b, Extended Data 1f). VCAM1+ 122 
erythroblastic island (EI) macrophages were validated as a distinct cell state as a result of 123 
their interactions with erythroid cells (Extended Data 4a-f).  We applied a descriptive 124 
nomenclature based on gene expression profiles.  All cell states are found throughout the 125 
developmental period studied, but frequency varied by gestation stage (Figure 1c and 126 
Extended Data 1e).  Neutrophils, basophils and eosinophils are not detected, consistent with 127 
reports of granulocytes emerging during fetal BM haematopoiesis7. Early stage samples show 128 
erythroid lineage bias, with later lymphoid and myeloid lineages representation, as previously 129 
shown5 (Figure 1c and Extended Data 1g). 130 
 131 
5 
Our fetal liver dataset can be explored using an interactive web portal through the following 132 
weblink: https://developmentcellatlas.ncl.ac.uk//datasets/hca_liver/. We provide 133 
comprehensive expression profiles of genes known to cause primary immunodeficiencies8 to 134 
aid future molecular phenotyping of these disorders (Extended Data 8).   135 
   136 
Validation of selected differentially expressed genes and cell states 137 
We manually selected 48 genes from the 4,471 differentially expressed genes between all 138 
clusters (log fold change >0.5) (Figure 2a).  The predictive power of these 48 genes to 139 
determine cell states by the Random Forest classifier was on average 89% for precision and 140 
recall (Extended Data 2a).  We designed a FACS panel for prospective cell isolation using 141 
genes encoding surface proteins (Figure 2a, Extended Data 9b), permitting validation of 19 142 
cell types by mini-bulk transcriptome profiling (6 of the 19 cell types also by scRNA-seq) 143 
using Smart-seq2 (Extended Data 2b-d).  Cytospins from FACS-isolated cells are 144 
morphologically consistent with their designated cell type, including hypogranularity of 145 
embryonic/fetal mast cells9 and early erythroid cells resemblance to the previously reported 146 
‘early erythroid progenitors’ (Figure 2b)10.   147 
 148 
Next, we evaluated the spatial distribution of erythroid, mast cell, myeloid and lymphoid 149 
lineages using imaging mass cytometry (Figure 2c).  The liver architecture evolves 150 
considerably between 8 and 15 PCW.  Organization of hepatocyte aggregates increases, 151 
though hepatic lobules around a central vein and portal triad are not clearly visible.  152 
Haematopoietic islands are present in sinusoids and surrounding hepatocyte aggregates.  153 
Sinusoidal CD68+ macrophages are surrounded by GlycophorinA (GYPA)+ erythroid cells 154 
(Figure 2c).  CD1c+ DCs and CD79a/CD20+ cells from the B-lineage are sparsely distributed 155 
(Figure 2c).  Cell proportions approximate our scRNA-seq profile for haematopoietic cells 156 
but not hepatocytes (Figure 2c and Figure 1b), in keeping with the fragility of hepatocytes 157 
following ex vivo isolation and their high expression of mitochondrial genes11.  By validating 158 
our single cell transcriptome dataset with multiple modalities, we provide an integrated map 159 
of haematopoietic cells in the fetal liver.  160 
 161 
Fetal liver and NLT haematopoiesis  162 
Next, we inferred trajectories of haematopoietic development.  By force directed graph 163 
(FDG), we identify three connections to a central HSC/MPP node featuring erythroid-164 
megakaryocyte-mast cells, B cell and innate/T-lymphoid cells and myeloid cells (Figure 3a 165 
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and Supplementary Video 1).  Partition based approximate graph abstraction (PAGA) also 166 
supports the presence of a shared megakaryocyte-erythroid-mast cell progenitor (MEMP) 167 
downstream of HSC/MPP (Extended Data 3a).  Genes dynamically modulated in the 168 
specification of erythroid, megakaryocyte and mast cell lineages are distinct:  TAL1 and 169 
KLF1 in erythroid; F11R, PBX1 and MEIS1 in megakaryocyte; and HES1 in mast cell 170 
differentiation (Extended Data 3b)12–15.  We explored supporting factors for fetal liver 171 
erythropoiesis using CellPhoneDB16 to predict specific/enriched receptor-ligand interactions 172 
between erythroblasts and VCAM1+ EI macrophages (Extended Data 4a).  We identify 173 
statistically significant interactions for VCAM1, ITGB1, ITGA4, SIGLEC1, ICAM4 and SPN, 174 
molecules known to be important in haematopoiesis (Extended Data 4a)17,18.  The presence of 175 
VCAM1 on EI macrophages and ITGA4 on early/mid erythroid cells is confirmed by 176 
immunohistochemical analysis on serial fetal liver sections (Extended Data 4b).  VCAM1+ EI 177 
macrophage interaction with erythroblasts is also observed using Imaging Flow Cytometry 178 
ImageStream analysis (Extended Data 4d) and may explain their combined erythroblast and 179 
macrophage transcriptome (Figure 2a), which has also been described in mouse central EI 180 
macrophages (Extended Data 4g)19. 181 
  182 
Comparing across haematopoietic tissues, mast cells are also present in yolk sac (Extended 183 
Data 1b).  Erythroblasts show expression of haemoglobin genes, and a temporal shift from 184 
Gower 1 and 2 subunit expression (HBZ, HBE1) to fetal haemoglobin subunit expression 185 
(HBA1 and HBG2) between yolk sac and liver (Figure 3b). 186 
 187 
Megakaryocytes, erythroid cells, mast cells and MEMP, are present in NLT, but HSC/MPPs 188 
are absent (Extended Data 1a, Extended Data 3c-d).  We compared the highly expressed and 189 
differentially expressed genes of corresponding cell types in fetal liver, skin and kidney 190 
(Figure 3c).  Mast cells, megakaryocytes and cells of the erythroid lineages show high 191 
connectivity (PAGA scores) across all four tissues (Extended Data 3d).  Local maturation of 192 
progenitors in NLT or influx of cells at various differentiation stages are two possibilities.  193 
Erythroid cells are absent in kidney, suggesting restricted differentiation of the MEMP 194 
lineage in certain sites (Extended Data 1a, Figure 3c).  Immunohistochemical analysis of 195 
serial skin sections show nucleated GYPA+ cells inside and outside of CD34+ blood vessels, 196 
in keeping with local differentiation of MEMPs (Figure 3d).  Light sheet fluorescence 197 
microscopy supported this finding (Figure 3e, Supplementary Video 2).  The proliferative 198 
capacity of MEMP in NLT is confirmed using MKI67 and cell cycle gene expression 199 
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(Extended Data 3e).  Skin MEMP express some early erythroblast genes including MYL4 200 
(Figure 3c)20, suggesting that these may act as erythroid progenitors in situ in the skin.  These 201 
findings demonstrate that during early development, the skin in physiological state can 202 
contribute to erythropoiesis and supplement fetal liver erythroid output.   203 
 204 
 205 
Lymphoid lineages in fetal liver and NLT 206 
Previous studies have reported the presence of T and B lymphocytes21, NK cells22, and 207 
ILCs23 in the human fetal liver.  We observe two lymphoid branches; an NK/T/ILC lineage 208 
and a B-lineage (Figure 4a and Extended Data 5a).  The ‘early lymphoid/T lymphocyte’ 209 
cluster varies by gestational stage, with cells expressing GATA3, KLRB1, CD3D, CD7 and 210 
JCHAIN at 7-8PCW before T cells emerge from the thymus (Figure 4a and Extended Data 211 
5b-c).  Early in gestation, this cluster may contain the fetal liver early thymocyte progenitor, 212 
which is capable of generating αβT cells upon co-culture with thymic epithelial cells24,25.  At 213 
the 12-14 PCW stage, cells express TRDC and TRAC, but no GZMB or PRF1, the 214 
cytoplasmic granular products characteristic of mature CD8+ T cells.  TRDC expression is 215 
absent at the 15-17 PCW stage (Extended Data 5b-d).  These findings are in keeping with the 216 
seeding of fetal liver by γδT cells and αβT cells sequentially following their exit from thymus 217 
after 12 PCW26 and are consistent with previous reports of T cell identification only after 18 218 
PCW25,27. 219 
 220 
NK cells (expressing NCAM1, CD7, IL2RB and CD3E) and ILC precursors (expressing KIT, 221 
KLRB1, IL7R, RORC) share a common origin in the lymphoid branch by PAGA and 222 
diffusion map analyses (Figure 2a, 4a, Extended Data 5a, 5h and Supplementary Table 3).  223 
This is in keeping with existing literature of a shared progenitor for NK and ILCs in human 224 
and  225 
mouse28,29. 226 
 227 
The B-lineage cells are a continuum of differentiation states, from primitive ‘pre pro-B’ 228 
clusters expressing CD34, SPINK2, and IGLL1 to ‘pro-B’ and ‘pre-B’ clusters with 229 
increasing expression of B cell transcripts MS4A1, CD79B, DNTT and HLA-DRA and 230 
reducing expression of JCHAIN and LTB30 (Figure 2a, 4a and Supplementary Table 3).  231 
‘Pro/pre-B’ cell clusters have high nuclear to cytoplasmic ratio, immature chromatin and 232 
nucleoli (Extended Data 5e).  Differentially regulated genes in the HSC/MPPs to B cell 233 
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transition include SPIB, SP100 and CTSS (Extended Data 5e).  Pre-B cells are detected 234 
between 7-8 PCW, but mature B cells only after 9 PCW (Figure 1b-c and 4a).  We observe a 235 
decline in HSC/MPP expression of NFKBIA, an inhibitor of NF-κB, and an increase in 236 
Kupffer cell TNFSF13B (BAFF) expression with gestation (Extended Data 5f).  NF-κB and 237 
BAFF are known B cell survival and differentiation factors31.  The cell-intrinsic versus 238 
tissue-microenvironment factors controlling B cell differentiation in the fetal liver require 239 
further investigation.       240 
 241 
Comparing liver with yolk sac and NLT, pro-B, pre-B and B cells are present in NLT but 242 
HSC/MPPs and pre pro-B cells are absent (Figure 4b and Extended Data 5g).  NK cell 243 
precursors, NK cells and ILC in NLT share a transcriptional signature with their liver 244 
counterparts, however tissue-specific expression of chemokine (XCLI, CXCL8) and cytotoxic 245 
granule genes (GNLY) suggest maturation and tissue adaptation in the skin and kidney 246 
(Figure 4c).  ILC precursors in NLT lack the full characteristic markers and TFs of their 247 
mature progenies; ILC1, ILC2 and ILC3 (Extended Data 5h).  NK cells and ILC precursors 248 
are present in yolk sac (Figure 4b).  Together, these findings suggest that NLTs are seeded by 249 
NK and ILC precursors from fetal liver and potentially yolk sac, which differentiate in situ 250 
and acquire tissue-related gene expression profiles.     251 
 252 
Tissue signatures in developing myeloid cells  253 
In mice, fate-mapping studies have demonstrated that tissue macrophages are seeded by yolk 254 
sac and fetal liver progenitors32,33, while dendritic cells (DCs) originate from BM-derived 255 
HSC/MPPs through a monocyte-independent lineage34.  We observe myeloid progenitors, 256 
monocytes, macrophages, DC1 and DC2 in fetal liver and NLT as early as 7 PCW (Figure 257 
1b, 5a-b, Extended Data 1a, 6a).   258 
 259 
Myeloid lineages stem from HSC/MPP via three intermediates: a neutrophil-myeloid 260 
progenitor expressing CD34, SPINK2, AZU1, PRTN3, ELANE, MPO and LYZ, monocyte- 261 
and DC- precursors (Figure 2a, Figure 3a and Supplementary Table 3).  DC1 differentiate 262 
from neutrophil-myeloid progenitors and DC-precursors link closely to DC2.   DC and 263 
monocyte differentiation involve dynamic regulation of CLEC11A, BATF3 and ID2 while 264 
monocyte differentiation involves S100A8/A9, FCGR1A/2A and S100A12 (Extended Data 265 
6b).  Plasmacytoid DC (pDC) precursors branch from both early myeloid precursors and pre 266 
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pro-B cells in keeping with recent reports of their mixed lymphoid and myeloid origin in 267 
mice (Extended Data 6a)35,36.  We compared monocytes, macrophages and their putative 268 
precursors between placenta, yolk sac and fetal liver (Figure 5a-b and Extended Data 6c).  269 
The macrophage transcriptome profile is highly tissue specific, showing connectivity to other 270 
macrophage subtypes within their tissue of residence and obscuring potential ontogenic 271 
relationships (Figure 5a-b and Extended Data 6c-e). 272 
 273 
Monocytes, macrophages, pDC, DC1 and DC2 are present in both skin and kidney (Extended 274 
Data 1a).  NLT monocytes and DCs correlate strongly to fetal liver counterparts but 275 
macrophages are more tissue-specific, with VCAM1 expression in liver and F13A1 in skin, as 276 
is observed in adult tissue macrophages37,38 (Extended Data 6e). Tissue specific gene 277 
expression patterns conferring functional specialization are discernible for DCs, for example 278 
S100A4 in skin DC1 (a molecule involved in T cell activation)39 and AOAH in liver DC2 (an 279 
enzyme involved in lipopolysaccharide response modulation)40 (Extended Data 6e).  DC 280 
activation despite the sterile fetal environment suggests an active role for fetal DCs in 281 
mediating tolerance as previously reported41.  282 
   283 
HSC/MPP differentiation potential by gestation  284 
Our observation of an HSC/MPP cell state from which the earliest lineage-committed cells 285 
radiate is in keeping with recent observations from scRNA-seq analysis in post-natal mice 286 
and humans35,42,43 (Figure 6a).  At the base of this cluster by FDG visualization is a 287 
population expressing CLEC9A, HLA-DRA and highest levels of primitive genes including 288 
MLLT3 consistent with a multipotent long-term repopulating (LT)-HSC (Figure 6a-b)44.  289 
Using differentially expressed genes and supervised analysis, HSC/MPP clusters with gene 290 
expression intermediate between LT-HSC and early progenitors similar to human lymphoid-291 
primed short-term (ST)-HSCs44, the mouse erythroid-biased MMP2, and myeloid-biased 292 
MMP345,46 are identifiable, demonstrating early transcriptome priming along all 293 
differentiation branches within the MPP pool (Figure 6a-b).      294 
 295 
We hypothesized that the cellular composition of the developing fetal liver resulted from 296 
local modulation of HSC/MPP potential.  To test this, we FACS-isolated single cells from the 297 
CD34+CD38+, CD34+CD38-CD45RA- and CD34+CD38-CD45RA+ FACS gates and profiled 298 
them by both plate-based single cell transcriptomics (Smart-seq2) and single cell clonal 299 
differentiation assays44,47 (Extended Data 7a).  A support vector machine trained on the fetal 300 
10 
liver dataset identified enrichment of HSC/MPPs (~85%) in the CD34+CD38- gate, with the 301 
majority of cells in the CD34+CD38-CD45RA+ MLP gate also classified as HSC/MPP 302 
(Extended Data 7b).   This is in agreement with reported transcriptional similarity between 303 
HSC/MPP and MLP78 and our identification of lymphoid priming in the HSC/MPP 304 
compartment.  Single cell culture from CD34+CD38-CD45RA- HSC/MPPs yield both uni- 305 
and multipotential colonies (Figure 6c-e and Extended Data 7c-g).  There is a significant 306 
reduction in trilineage colonies with gestational age (Extended Data 7f).  Colonies containing 307 
erythroid cells significantly decrease while those containing NK cells and B cells increase 308 
with gestational age (Figure 6c-e, Extended Data 7c-g).   HSC/MPP from <9 PCW 309 
embryonic livers generate almost no B cells (Figure 6e), in keeping with the paucity of B 310 
cells at this stage (Figure 1c, 4a and Extended Data 1g).  These findings support the 311 
hypothesis of differential HSC/MPP intrinsic potential by gestational stage and mirror our 312 
observation of early erythroid predominance and greater lymphoid representation at later 313 
stages (Figure 1c and Figure 4a).   314 
 315 
Comparing HSC/MPPs and early progenitors across haematopoietic tissues during 316 
development, higher MKI67 expression and cell cycle staining suggest enhanced proliferative 317 
potential of yolk sac and fetal liver progenitors/HSC/MPPs48–50 (Extended Data 7h).  The 318 
fraction of fetal liver HSC/MPP in G0 increases with gestational age (Figure 6f, Extended 319 
Data 7i), indicating a progressive shift to quiescence during fetal life.  Fetal liver HSC/MPP 320 
have higher expression of genes encoding a heat shock protein (HSPA1A), potentially for 321 
maintenance of genome and proteome integrity, and lower levels of MHC-I (HLA-B) 322 
suggesting reduced antigen presenting potential compared to cord blood and adult BM 323 
HSC/MPPs (Figure 6g).  324 
 325 
Collectively, our findings demonstrate that intrinsic changes in HSC/MPP numbers, 326 
proliferation and differentiation potential occur over the first and second developmental 327 
trimesters.  These changes are likely to be pivotal for fetal liver haematopoiesis to adapt to 328 
the needs of the developing fetus; first the establishment of an effective oxygen transport 329 
system and subsequently the development of a complete blood and immune system.    330 
 331 
Discussion  332 
Development of the human immune system in utero has remained poorly understood.  Using 333 
single cell transcriptome profiling, we resolve the cellular heterogeneity and abstract dynamic 334 
11 
temporal information on blood and immune development in fetal liver, yolk sac, skin and 335 
kidney.  Large scale scRNA-seq studies during human development must account for 336 
technical batch effects without compromising detection of biological variations over 337 
gestation.  Our approach highlights key insights; physiological erythropoiesis in fetal skin, 338 
establishment of DC network as early as 7 PCW, potential dual myeloid and lymphoid origin 339 
of pDCs, seeding of mast cells, NK and ILCs from the yolk sac and tissue adaptation of NKs, 340 
ILCs, DCs and macrophages during development.  Our findings reveal modulation of 341 
HSC/MPP intrinsic differentiation potential over gestation age suggesting this as an 342 
additional functional mechanism to regulate haematopoietic output of the fetal liver 343 
throughout the first and second trimesters.  344 
In summary, our comprehensive fetal liver atlas provides a foundational resource for 345 
understanding fetal liver haematopoiesis and the developing immune system.  Our reference 346 
dataset will be invaluable for studies on paediatric blood and immune disorders and 347 
exploiting HSC/MPPs for therapy.  Our approach using single cell transcriptomics to study 348 
human development provides a framework that can be applied to study any temporal 349 
processes across the human lifespan.   350 
 351 
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Figure Legends 470 
Figure 1: Single cell transcriptome map of fetal liver.  a, Schematic of tissue processing 471 
and cell isolation for scRNA-seq profiling of fetal liver, skin and kidney across four 472 
developmental stages (7-8, 9-11, 12-14, and 15-17 post conception weeks (PCW)), and yolk 473 
sac from 4-7 PCW. SS2, Smart-seq2. b, UMAP visualisation of fetal liver cells from 10x 474 
using 3’ chemistry. Colours indicate cell state. HSC/MPP, haematopoietic stem 475 
cell/multipotent progenitor; ILC, innate lymphoid cell; NK, natural killer cell; Neut-myeloid, 476 
neutrophil-myeloid; DC, dendritic cell; pDC, plasmacytoid DC; Mono-mac, monocyte-477 
macrophage; EI, erythroblastic island; Early L/TL, Early lymphoid/T lymphocyte; MEMP, 478 
megakaryocyte-erythroid-mast cell progenitor. Statistical significance of cell frequency 479 
change by stage shown in parentheses (negative binomial regression with bootstrap 480 
correction for sort gates; * p < 0.05, *** p < 0.001, and **** p < 0.0001 as per SI Table 8) 481 
with up/down arrows to indicate positive/negative coefficient of change, respectively. c, 482 
Liver composition by developmental stage as the mean percentage of each population per 483 
stage corrected by CD45+/CD45- sort fraction. Colours indicate cell states as shown in b. 484 
 485 
Figure 2: Multi-modal and spatial validation of cell types.  a, Median scaled ln-486 
normalised gene expression of 48 selected differentially expressed genes for the liver cell 487 
states from 1b visualised by dot; asterisk (*) indicates markers used for FACS-isolation of 488 
cells. Gene expression frequency (% cells within cell type expressing) indicated by spot size 489 
and expression level by colour intensity. b, Representative Giemsa-stained cytospins showing 490 
morphology of populations isolated by FACS based on differentially expressed genes with * 491 
in a. Scale bar, 10μm. c, Overlay pseudo-colour Hyperion representative images for 8 PCW 492 
and 15 PCW fetal liver. Far left images are shown at 5x magnification with zoom of insets on 493 
right at 20x magnification (1μm/pixel). Bile ducts are marked with an *. 494 
 495 
Figure 3: Fetal liver and NLT haematopoiesis.  a, Force-directed graph (FDG) 496 
visualisation of all haematopoietic cells from 1b. b, Dot plot showing the median scaled ln-497 
normalised expression of globin genes encoding haemoglobin subunits; HBZ and HBE1 498 
(Gower 1), HBE1 and HBA1 (Gower 2) and HBA1 and HBG2 (fetal) in liver, skin, and yolk 499 
sac erythroid lineages (MEMP, early, mid and late erythroids). Gene expression frequency 500 
(% cells within cell type expressing) indicated by spot size and expression level by colour 501 
intensity. c, Heat map showing the scaled ln-expression of selected marker genes in fetal 502 
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liver, NLT and yolk sac subsets. d, Representative immunohistochemical staining of 503 
sequential sections of 8 PCW fetal skin for endothelium (CD34+) and erythroblasts 504 
(nucleated and GYPA+), nuclei stained with blue alkaline phosphatase. Zoom in of insets 505 
(right) bordered with black (top) indicate nucleated cells stained positive for GYPA within 506 
CD34+ blood vessels, and those bordered with red (bottom) indicate nucleated GYPA+ cells 507 
outside CD34+ blood vessels. Scale bar, 100μm. e, Representative light sheet fluorescence 508 
microscopy of embryo (5 PCW) hand skin. Scale bar, 5μm; TO-PRO-3/nuclei = red, GYPA = 509 
green (see also Supplementary Video 2). < indicates extravascular nucleated erythroid cells.  510 
 511 
Figure 4: Lymphoid lineages in fetal liver and NLT.  a, FDG visualisation of fetal liver 512 
HSC/MPP and lymphoid cell types from 1b showing changes over four developmental 513 
stages. b, FDG visualisation of fetal liver and corresponding skin, kidney and yolk sac 514 
lymphoid cells. c, ln-normalised median expression of selected known NK (left) and ILC 515 
precursor (right) marker genes and selected differentially expressed genes between liver 516 
(red), skin (blue) and kidney (green) visualised by violin plots (*** p < 0.005; **** p < 517 
0.001).  518 
 519 
Figure 5: Tissue signatures in developing myeloid cells. a, FDG visualisation of 520 
HSC/MPP, myeloid progenitors, monocytes and macrophages from fetal liver, 521 
decidua/placenta and yolk sac. Mac, Macrophage; Monocyte prec., Monocyte precursor; 522 
Neut-myeloid prog., Neutrophil-myeloid progenitor. b, PAGA connectivity scores of the 523 
populations shown in a.  524 
 525 
Figure 6: HSC/MPP differentiation potential by gestation. a, FDG visualisation of liver 526 
HSC/MPP and early haematopoietic progenitor populations from Figure 1b. b, Violin plots 527 
showing ln-normalised median gene expression of statistically significant, dynamically 528 
variable genes that are up or downregulated during HSC/MPP transition to neutrophil-529 
myeloid progenitors, MEMP and pre pro-B cells from fetal liver. Bar and ‘ns’ indicate not 530 
significant. H/M, HSC/MPP. c, Stacked barplot of all different types of colonies generated by 531 
single ‘HSC pool’ gate cells in an assay with MS5 stroma. * p < 0.05, *** p < 0.001, 532 
individual samples shown in Extended Data 7c. The colour of the stat bar corresponds to the 533 
type of colony tested vs all others. My, Myeloid; Ery, Erythroid, Meg, Megakaryocyte. d, 534 
Percentage of colonies generated by single ‘HSC pool’ gate cells containing erythroid cells 535 
(defined as the sum of Ery, Ery/Meg, Ery/Meg/My, Ery/My, Ery/NK and Ery/NK/My 536 
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colonies shown in c), *** p < 0.001. My, Myeloid; Ery, Erythroid; Meg, Megakaryocyte.  e, 537 
Percentage of colonies containing B cells following culture in B/NK optimized conditions 538 
from 10 cells from ‘HSC pool’ gate (** p < 0.01). f, Mean +/- s.d. percentage of cells in the 539 
G0 phase of the cell cycle assessed using Ki67 and DAPI flow cytometry analysis (* p = 540 
0.0136). g, ln-normalised median expression of selected genes in yolk sac progenitors, cord 541 
blood HSC and adult bone marrow HSC with significant differential expression compared to 542 
fetal liver HSC/MPP, visualised by violin plots (**** p < 0.0001). 543 
 544 
Extended Data 1: Single cell transcriptome map of fetal liver.  a, Fetal skin and kidney 545 
haematopoietic cells visualised by UMAP. Colours indicate cell state. Inset: colours indicate 546 
tissue type. b, UMAP visualisation of yolk sac haematopoietic cells.  Colours indicate cell 547 
state. Inset: colours indicate location within yolk sac. c, UMAP visualisation of 3’ liver 10x 548 
cells post batch correction, coloured by sample. d, UMAP visualisation (top) of 3’ 10x liver 549 
sample sex mixing grouped by developmental stage, and violin plots (bottom) showing ln-550 
normalised median expression of XIST (green) and RSP4Y1 (purple), which marks female 551 
and male samples respectively. e, UMAP visualisation of fetal liver composition by 552 
developmental stage. Colours indicate cell state. f, UMAP visualisation of fetal liver cells 553 
profiled using Smart-seq2. Colours indicate cell states as shown in e.  g, Frequency (mean +/- 554 
s.e.m.) of B cells in the CD34- cells detected in 6-19 PCW fetal livers by flow cytometry (* p 555 
< 0.05; *** p = 0.003; **** p < 0.001). 556 
 557 
Extended Data 2: Transcriptome validation of fetal liver cells. a, Assessment of 48 genes 558 
from the 4,471 highly variable genes by using a Random Forest classifier to assign cell 559 
labels, where ‘true cell label’ indicates the manual annotation based on the full list of variable 560 
genes. b, Comparison of representative mini bulk RNAseq data (in coloured triangles) and 561 
liver erythroblastic island (EI) populations (early, mid and late erythroids, VCAM1+ EI 562 
macrophages), Kupffer cells and endothelium validated by SS2 (in colour) overlaid on whole 563 
liver SS2 populations (grey). c, Dot plot showing representative median scaled ln-normalised 564 
gene expression of 100 FACS-isolated liver cells based on marker gene expression in Figure 565 
2a. Gene expression indicated by spot size and colour intensity. d, Dot plot showing median 566 
scaled ln-normalised gene expression of FACS sorted single cells from liver erythroblastic 567 
island (EI) populations (early, mid and late erythroids, VCAM1+ EI macrophages), Kupffer 568 
cells and endothelium shown as coloured dots in b based on marker gene expression in 569 
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Figure 2a. Gene expression frequency (% cells within cell type expressing) indicated by spot 570 
size and expression level by colour intensity. 571 
 572 
Extended Data 3: Fetal liver and NLT haematopoiesis.  a, PAGA analysis of fetal liver 573 
HSC/MPP, erythroid, megakaryocyte and mast cell lineages from Figure 3a. Lines 574 
symbolise connection; line thickness corresponds to the level of connectivity (thin to thick = 575 
low to high PAGA connectivity). b, Heat map showing min-max normalised expression of 576 
statistically significant (p < 0.001), dynamically variable genes from pseudotime analysis for 577 
erythroid, megakaryocyte and mast cell inferred trajectories. Transcription factors in bold, 578 
asterisk (*) mark genes not previously implicated for the respective lineages. c, FDG 579 
visualisation of fetal liver, skin and kidney HSC/MPP, MEMP, erythroid, megakaryocyte and 580 
mast cell lineages.  d, PAGA connectivity scores of HSC/MPP, erythroid, megakaryocyte 581 
and mast cell lineages between fetal liver, skin, kidney (K) and yolk sac.  e, Stacked barplots 582 
(right) of the mean +/- s.d. percent of fetal liver (red), skin (blue) and kidney (green) 583 
HSC/MPP, MEMP, Erythroid, Megakaryocyte and Mast cells in each stage of the cell cycle 584 
(G1 (navy), G2M (blue), and S (white) phase), and ln-normalised median expression of 585 
MKI67 transcript (right) in corresponding liver vs NLT cell types (total percent of MKI67 586 
expressing cells stated above plots; each dot represents a single cell). * p < 0.05; ** p < 0.01; 587 
*** p < 0.005.  588 
 589 
Extended Data 4: Investigation of interactions between fetal liver macrophages and 590 
erythroid cells. a, Representative immunohistochemical staining of fetal liver for 591 
erythroblasts and macrophages with GYPA and CD68, respectively. Scale bar, 50μm. 592 
Statistically significantly (p < 0.05) enriched receptor-ligand interactions from CellPhoneDB 593 
between VCAM1+ EI macrophages (purple) and two erythroid populations (early and mid; 594 
red) (n = 14 biologically independent samples). Asterisk (*) indicate protein complexes. 595 
Violin plots show ln-normalised median gene expression value of VCAM1 and ITGA4 in 596 
cells analysed by CellPhoneDB (marked by # in dot plot). b, Representative 597 
immunohistochemical staining of sequential sections of 8 PCW fetal liver for VCAM1+ EI 598 
macrophages (VCAM1+) and CD49d+GYPA+ cells with nuclei stained using blue alkaline 599 
phosphatase. Zoom in of insets (right) with coloured arrows indicating erythroblast (yellow) 600 
and VCAM1+ EI macrophage (purple). Scale bar, 100μm. c, Representative gating strategy 601 
used to visualise fetal liver erythroid cells, VCAM1+ EI macrophages, Kupffer cells, Mono-602 
macs, and mast cells. d, Bright field, VCAM1 (CD106), CD34, CD45, KIT (CD117), GYPA, 603 
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CD14, and HLA-DR images for each cell type within gates shown in c. e, Representative 604 
bright field images of cells found within the single cell and doublet gates. f, Barplots showing 605 
the mean +/- s.d. proportion of each cell type within the single cell gate (white) or doublet 606 
gate (grey); * p = 0.0194. g, Comparison of macrophage and erythroid gene expression in 607 
mouse macrophages (red) and EI macrophages (blue), n = 3 from Li et al.19. 608 
 609 
Extended Data 5: Lymphoid lineages in fetal liver and NLT.  a, PAGA analysis of fetal 610 
liver HSC/MPP and lymphoid cell types from Figure 1b showing changes over four 611 
developmental stages. Lines symbolise connection; line thickness corresponds to the level of 612 
connectivity (thin to thick = low to high PAGA connectivity). b, Feature plots and c, violin 613 
plots showing ln-normalised median expression of selected known NK, ILC and T cell genes 614 
over gestation for early lymphoid/T lymphocyte cluster; ** p < 0.001; *** p < 0.005; **** p 615 
< 0.0001.  d, Dot plot showing median scaled ln-normalised median expression of V(D)J 616 
transcripts in fetal liver lymphoid cell types. Gene expression indicated by spot size and 617 
colour intensity.  e, Heat map showing normalised expression of statistically significant, 618 
dynamically variable genes from pseudotime analysis for B cell lineage inferred trajectory 619 
(likelihood ratio test). Transcription factors are in bold.  Morphology of liver Pro/Pre B cells 620 
and B cells by Giemsa stain after cytospin.   f, ln-normalised expression (mean +/- s.e.m.) of 621 
TNFSF13B in Kupffer cells and NFKBIA in HSC/MPPs and cells in the B cell lineage across 622 
4 developmental stages spanning 6-17 PCW; trend lines showing linear regression.  g, PAGA 623 
connectivity scores of HSC/MPP and lymphoid cells from fetal liver, skin, kidney and yolk 624 
sac. h, Violin plots showing ln-normalised median expression of selected known ILC and NK 625 
cell genes expressed in ILC precursors from fetal liver, skin, and kidney. 626 
 627 
Extended Data 6: Tissue signatures in developing myeloid cells. a, Diffusion map of fetal 628 
liver HSC/MPP, progenitors and precursors from 1b. b, Heat map showing min-max 629 
normalised expression (p < 0.001) of dynamically variable genes from pseudotime analysis 630 
for monocyte, DC1 and DC2 inferred trajectories. Transcription factors in bold, * mark genes 631 
not previously implicated for the respective lineages. c, Heat map visualisation comparing 632 
scaled expression of the top marker genes of decidua/placenta (red), fetal liver (black) and 633 
yolk sac (purple) progenitor and myeloid populations. d, PAGA connectivity scores of 634 
HSC/MPP and myeloid cells from fetal liver, skin and kidney. e, ln-normalised median 635 
expression of 3 known marker genes & 3 differentially expressed genes in corresponding 636 
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myeloid populations across fetal liver, skin and kidney visualised by violin plots (* p < 0.05; 637 
*** p < 0.005; **** p < 0.0001). 638 
 639 
Extended Data 7: HSC/MPP differentiation potential by gestation. a, Experimental 640 
design for single cell transcriptome and culture of fetal liver cells from representative FACS 641 
gates illustrated. b, Alignment of 349 scRNA-seq profiled cells from FACS gates in a with 642 
10x profiled HSC/MPPs and early progenitors visualised using FDG, point shape 643 
corresponds to sequencing type (triangle = SS2 plate data, circle = 10X data). c, Stacked 644 
barplot of all different types of colonies generated by single ‘HSC pool’ gate cells (gate 645 
defined in a). d, Stacked bar plot of all different types of colonies generated by single ‘HSC 646 
pool’ gate cells without MS5 stroma layer (gate defined in a) by stage (left) and in individual 647 
samples (right), * p < 0.05. e, Percentage of colonies generated by single ‘HSC pool’ cells 648 
without MS5 stroma layer containing erythroid cells (sum of Ery, Ery/Meg, Ery/Meg/My, 649 
and Ery/My colonies shown in c), ** p < 0.01. f, Percentage of colonies from single cell 650 
culture (shown in 6c) that differentiated along 3 lineages (defined as sum of Ery/NK/My and 651 
Ery/Meg/My colonies) branches (*** p < 0.005). g, Percentage of colonies containing NK 652 
cells following B/NK optimised culture of 10 cells from ‘HSC pool’ gate (* p < 0.05, ** p < 653 
0.01). h, Percentage (Mean +/- s.e.m.) of HSC/MPP and early progenitors in fetal liver, yolk 654 
sac, cord blood and adult bone marrow expressing MKI67 (* p < 0.05, ** p < 0.01, **** p < 655 
0.001).  i, Mean +/- s.d. percentage of CD34+CD38- and CD34+CD38+cells in the indicated 656 
cell cycle phases (right) as determined by flow cytometry analysis (left, representative plot of 657 
n = 8 biologically independent samples) (G0: Ki67-DAPI-, G1: Ki67+DAPI-, S-G2-M: 658 
Ki67+DAPI+ (left)).  659 
 660 
Extended Data 8: Expression of known Primary Immunodeficiency (PID)-linked genes 661 
in fetal liver. Dot plots showing relative expression of genes known to be associated with 662 
major PID disease categories in fetal liver cell types from Figure 1b. Early L/T L, Early 663 
lymphoid/T lymphocyte. Gene expression frequency (% cells within cell type expressing) 664 
indicated by spot size and expression level by colour intensity.  665 
 666 
Extended Data 9: FACS gating strategy for scRNA-seq analysis. a, Gating strategy used 667 
to FACS-isolate cells for droplet-(10x) and plate-based scRNA-seq (Smart-seq2) for samples 668 
F2-F17. b, Gating strategy used to FACS-isolate cells for cytospins, scRNA-seq (Smart-seq2) 669 
and 100 cell RNA-seq. c, Flow cytometry gating strategy used to identify the colonies 670 
21 
cultured in vitro from single cells as shown in Figure 6c. d, Flow cytometry gating strategy 671 
used to identify B and NK colonies cultured in vitro from 10 cells as shown in Figure 6e. 672 
  673 
Materials and methods 674 
Tissue Acquisition 675 
Human fetal tissues were obtained from the MRC/Wellcome Trust-funded Human 676 
Developmental Biology Resource (HDBR; http://www.hdbr.org)51 with appropriate written 677 
consent and approval from the Newcastle and North Tyneside NHS Health Authority Joint 678 
Ethics Committee (08/H0906/21+5). HDBR is regulated by the UK Human Tissue Authority 679 
(HTA; www.hta.gov.uk) and operates in accordance with the relevant HTA Codes of 680 
Practice.  681 
Embryos and fetal specimens used for light sheet fluorescence microscopy were obtained 682 
with written informed consent from the parents (Gynecology Hospital Jeanne de Flandres, 683 
Lille, France) with the approval of the local ethics committee (protocol N°PFS16-002). 684 
Tissues were made available in accordance with the French bylaw (Good practice concerning 685 
the conservation, transformation and transportation of human tissue to be used 686 
therapeutically, published on December 29, 1998). Permission to utilize human tissues was 687 
obtained from the French agency for biomedical research (Agence de la Biome ́decine, Saint-688 
Denis La Plaine, France). 689 
 690 
Tissue Processing 691 
All tissues were processed immediately after isolation using the same protocol. Tissue was 692 
transferred to a sterile 10mm2 tissue culture dish and cut into <1mm3 segments before being 693 
transferred to a 50mL conical tube. Yolk sac content was aspirated for analysis prior to yolk 694 
sac digestion.  Tissue was digested with 1.6mg/mL collagenase type IV (Worthington) in 695 
RPMI (Sigma-Aldrich) supplemented with 10%(v/v) heat-inactivated fetal bovine serum 696 
(Gibco), 100U/mL penicillin (Sigma-Aldrich), 0.1mg/mL streptomycin (Sigma-Aldrich), and 697 
2mM L-Glutamine (Sigma-Aldrich) for 30 minutes at 37°C with intermittent shaking. 698 
Digested tissue was passed through a 100μm filter, and cells collected by centrifugation 699 
(500g for 5 minutes at 4°C). Cells were treated with 1X RBC lysis buffer (eBioscience) for 5 700 
minutes at room temperature and washed once with flow buffer (PBS containing 5%(v/v) 701 
FBS and 2mM EDTA) prior to counting. 702 
 703 
Fetal developmental stage assignment and chromosomal assessment  704 
22 
Embryos up to 8 post conception weeks (PCW) were staged using the Carnegie staging 705 
method52.  After 8 PCW, developmental age was estimated from measurements of foot length 706 
and heel to knee length and compared against a standard growth chart53.  A piece of skin, or 707 
where this was not possible, chorionic villi tissue was collected from every sample for 708 
Quantitative Fluorescence-Polymerase Chain Reaction analysis using markers for the sex 709 
chromosomes and the following autosomes 13, 15, 16, 18, 21, 22, which are the most 710 
commonly seen chromosomal abnormalities.  All samples were karyotypically normal.  711 
 712 
Flow cytometry and FACS for scRNA-seq 713 
Antibody panels were designed to allow enrichment of cell fractions for sequencing and cell 714 
type validation. Antibodies used for FACS isolation are listed in Supplementary Table 14. An 715 
antibody cocktail was prepared fresh by adding 3μL of each antibody in 50μL Brilliant Stain 716 
Buffer (BD) per tissue. Cells (<10x106) were resuspended in 50-100μL flow buffer and an 717 
equal volume of antibody mix was added to cells from each tissue. Cells were stained for 30 718 
minutes on ice, washed with flow buffer and resuspended at 10x106 cells/mL. DAPI (Sigma-719 
Aldrich) was added to a final concentration of 3μM immediately prior to sorting. Flow 720 
sorting was performed on a BD FACSAria™ Fusion instrument using DIVAv8, and data 721 
analysed using FlowJo (v10.4.1, BD). Cells were gated to exclude dead cells and doublets, 722 
and then isolated for scRNA-seq analysis (10x or Smart-seq2). For 10x, cells were sorted into 723 
chilled FACS tubes coated with FBS and prefilled with 500μL sterile PBS. For Smart-seq2, 724 
single cells were index-sorted into 96-well lo-bind plates (Eppendorf) containing 10μL lysis 725 
buffer (TCL (Qiagen) + 1% (v/v) β-mercaptoethanol) per well.  B cells were also investigated 726 
by flow cytometry as per Roy et. al.54. 727 
 728 
Cytospins and mini bulk RNA-seq validation 729 
Fetal liver cells were immunostained with two separate panels (see Supplementary Table 15 730 
for antibody details). Cells were stained for 30 minutes on ice followed by DAPI staining. 731 
FACS was performed on a BD FACSAria™ Fusion instrument, and data analysed using 732 
FlowJo (v10.4.1).  Cells were isolated into chilled FACS tubes coated with FBS and prefilled 733 
with 500μL sterile PBS for cytospin (500 – 2000 cells), or into 1.5mL microfuge tubes 734 
containing 20μL lysis buffer (100 cells). Giemsa staining (Sigma-Aldrich) was used to 735 
determine the morphology of sorted cells on cytospins. Slides were viewed using a Zeiss 736 
AxioImager microscope, images taken of 4 fields from n = 3 samples using the 100x 737 
objective, and viewed using Zen (v2.3). 738 
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 739 
HSC/MPP Culture 740 
MS5 in log-phase growth (DSMZ, Germany, passage 6-10) were seeded into 96-well flat-741 
bottom plates (Nunclon delta surface; Thermo) at a density of 3000 cells per well 24 hours 742 
prior to sorting.  Medium was Myelocult H5100 (Stem Cell Technologies) supplemented 743 
with 100U/mL Penicillin and 0.1mg/mL Streptomycin (Sigma-Aldrich).  On the day of 744 
sorting, media were replaced with Stem Pro-34 SFM media (Life Technologies) 745 
supplemented with 100U/mL Penicillin and 0.1mg/mL Streptomycin, 2mM L-glutamine 746 
(Sigma-Aldrich), stem cell factor 100ng/ml (Miltenyi), Flt3 20ng/ml (Miltenyi), TPO 747 
100ng/ml (Miltenyi), EPO 3ng/ml (Eprex), IL-6 50ng/ml (Miltenyi), IL-3 10ng/ml 748 
(Miltenyi), IL-11 50ng/ml (Miltenyi), GM-CSF 20ng/ml (Miltenyi), IL-2 10ng/ml (Miltenyi), 749 
IL-7 20ng/ml (Miltenyi) and Lipids (hLDL) 50ng/ml (Life Technologies)44. 750 
 751 
Frozen fetal liver cells were thawed and stained with 10μl/106 cells of antibody cocktail (see 752 
Supplementary Table 16-17 for antibody details) for 30 minutes on ice. Three populations of 753 
HSC/MPPs and progenitors were isolated from fetal liver suspension.  Populations were 754 
identified from the DAPI-, doublet-excluded gate as CD3/CD16/CD11c/CD14/CD19/CD56-, 755 
CD34+ cells (see Supplementary Table 16 for antibody details).  The HSC/MPP pool and 756 
MLP were found within the 20% of cells with lowest CD38 expression: HSC/MPP pool were 757 
CD90+/- and CD45RA- whilst MLP were CD90-CD45RA+.  Progenitors with the highest 20% 758 
of CD38 expression were sorted for comparison.  Single cells were sorted using a BD 759 
FACSAria™ Fusion, and sorted directly onto MS5 or medium for culture, or into 96-well lo-760 
bind plates containing 10μl/well lysis buffer for Smart-seq2 scRNAseq (Supplementary 761 
Table 12). Single-cell-derived colonies analysis was performed as described by the Laurenti 762 
Lab44.  In brief, colonies were harvested into 96 U-bottom plates using a plate filter to 763 
prevent the carryover of MS5 cells. Cells were stained with 50μl/well of antibody cocktail 764 
(Supplementary Table 16-17 for antibody details), incubated for 20 minutes in the dark at 765 
room temperature and then washed with 100μl/well of PBS + 3% FBS. The type (lineage 766 
composition) and the size of the colonies formed were assessed by high-throughput flow 767 
cytometry (BD FACS Symphony). Colony output was determined using the gating strategy 768 
shown in Extended Data 9c. A single cell was defined as giving rise to a colony if the sum of 769 
cells detected in the CD45+ 5+ and GYPA+ gates was ≥ 30 cells. Erythroid colonies were 770 
identified as CD45−GYPA+ ≥ 30 cells, Megakaryocyte colonies as CD41+ ≥ 30 cells, Myeloid 771 
colonies as [(CD45+CD14+) + (CD45+CD15+)] ≥ 30 cells, NK colonies as CD45+CD56+ ≥ 30 772 
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cells.  All high-throughput screening flow cytometry data was recorded in a blinded way, and 773 
correlation between the colony phenotype and originating population was only performed at 774 
the final stage. Two-tailed Fisher’s exact test, performed in Prism (v8.1.2, GraphPad 775 
Software), were applied to the numbers of colonies of each type by stage to determine 776 
statistical significance in lineage differentiation potential with development.  For 777 
differentiation of B cells from HSC/MPP pool, 10 cells were sorted directly on MS5 stroma 778 
in the same conditions as Doulatov et al.47 (see Supplementary Table 17 for antibody details).  779 
An example of gating strategy is shown in Extended Figure 8d.   For Ki67 staining, cells were 780 
stained using antibody panel in Supplementary Table 18, CD34+ cells were sorted, 781 
fixed/permeabilised using the BD Cytofix/Cytoperm kit according to the manufacturer’s 782 
instructions and then stained overnight for Ki67-FITC followed by DAPI as a DNA dye.  783 
 784 
ImageStream analysis of fetal liver cell suspensions 785 
Frozen fetal liver cells were thawed and stained with the antibody cocktail (see 786 
Supplementary Table 19 for antibody details) for 30 minutes on ice. Cells were washed with 787 
flow buffer and resuspended at the same cell density employed for cell sorting experiments 788 
(10x106 cells/mL). DAPI (Sigma-Aldrich) was added to a final concentration of 3μM 789 
immediately prior to acquisition in order to identify and exclude dead cells from the 790 
experiment.  Samples were acquired on a fully calibrated ImageStream X MKII system 791 
(Luminex Corporation, USA) using 488nm, 561nm, 405nm and 642nm excitation lasers and 792 
the 60x magnification collection optic.  Laser powers were set in order to maximise signal 793 
resolution but minimise any saturation of the CCD camera with bright-field (BF) images 794 
collected in channels 1 and 9.  A minimum of 50,000 cell events were collected per sample.  795 
In order to calculate spectral compensation, single stained antibody capture beads were 796 
acquired with the bright-field illumination turned off.  Spectral compensation and data 797 
analysis were performed using the IDEAS analysis software (v6.2.64, Luminex Corp).  798 
Briefly, dead cells were first excluded based on DAPI positivity.  Overt doublets and debris 799 
were excluded from the live cell population using the aspect ratio and area of the BF image in 800 
channel 1.  Single cells had an intermediate area value and an aspect ratio between 1 and 0.6 801 
and were gated as such.  Overt doublets present as having an increased area and a lower 802 
aspect ratio value and were also gated as such.  In all cases the position and boundaries of a 803 
gate was checked for appropriateness using the underlying imagery.  The key cell types 804 
within the sample were then identified and gated using the total integrated (post-805 
compensation) fluorescence signals from each labelled antibody in the panel in an analogous 806 
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fashion to conventional flow cytometry data.  Each major cell type was then interrogated 807 
using the associated multi-spectral images for true single cell identity or for the presence of 808 
“pernicious doublets” (cells with either significant debris attached or large cells with much 809 
smaller cells attached).  The same phenotypic analysis was extended to the cells in the overt 810 
doublet gate. Further analysis was performed in FlowJo (v10.4.1). Kruskal-Wallis with 811 
Dunn’s post hoc, performed in Prism (v8.1.2, GraphPad Software), were applied to the 812 
proportion of each cell type found within the doublet gate to determine statistical significance 813 
in doublet rates across fetal liver cell types.  814 
 815 
Library Preparation and Sequencing 816 
For the droplet-encapsulation scRNA-seq experiments, 7,000 live, single, CD45+ or CD45- 817 
FACS-isolated cells were loaded onto each channel of a Chromium chip before encapsulation 818 
on the Chromium Controller (10x Genomics, Pleasanton, CA, USA).  Single cell sequencing 819 
libraries were generated using the Single Cell 3' v2 and V(D)J Reagent Kits (for T cell 820 
receptor repertoire analysis) as per the manufacturer’s protocol. Libraries were sequenced 821 
using an Illumina HiSeq 4000 using v4 SBS chemistry to achieve a minimum depth of 822 
50,000 raw reads per cell.  The libraries were sequenced using the following parameters: 823 
Read1: 26 cycles, i7: 8 cycles, i5: 0 cycles; Read2: 98 cycles to generate 75bp paired end 824 
reads.  825 
For the plate-based scRNA-seq experiments, a slightly modified Smart-seq2 protocol was 826 
used as previously described55.  After cDNA generation, libraries were prepared (384 cells 827 
per library) using the Illumina Nextera XT kit (Illumina Inc, San Diego, CA, USA).  Index v2 828 
sets A, B, C and D were used per library to barcode each cell before multiplexing.  Each 829 
library was sequenced to achieve a minimum depth of 1-2 million raw reads per cell using an 830 
Illumina HiSeq 4000 using v4 SBS chemistry to generate 75bp paired end reads.  831 
 832 
For the mini bulk RNA-seq experiments, each cell lysate was transferred into a 96-well lo-833 
bind plate (Eppendorf) then processed using the same modified Smart-seq2 protocol as 834 
described above. After cDNA generation, libraries were prepared using the Illumina 835 
NexteraXT kit with Index v2 set A to barcode each mini bulk library before multiplexing. All 836 
libraries were sequenced on one lane of an Illumina HiSeq 4000 using v4 SBS chemistry to 837 
generate 75bp paired end reads and aiming to achieve a minimum depth of 10 million reads 838 
per library. 839 
 840 
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Immunohistochemistry 841 
Formalin fixed, paraffin embedded blocks of fetal livers aged 6 PCW, 8 PCW, 10 PCW and 842 
13 PCW were obtained from the HDBR. Each was sectioned at 4μm thickness onto APES-843 
coated slides. Sections were dewaxed for 5 minutes in Xylene (Fisher Chemical) then 844 
rehydrated through graded ethanol (99%, 95% and 70%; Fisher Chemical) and washed in 845 
running water. Sections were treated with hydrogen peroxide block (1%v/v in water; Sigma) 846 
for 10 minutes and rinsed in tap water prior to antigen retrieval. Citrate antigen retrieval was 847 
used for all sections. Citrate buffer, pH6 was used with pressure heating for antigen retrieval, 848 
and then slides placed in TBS, pH7.6 for 5 minutes prior to staining. Staining was done using 849 
the Vector Immpress Kit (Vector Laboratories). Sections were blot dried and blocked 850 
sequentially with 2.5% normal horse serum, avidin (Vector Laboratories) and then biotin 851 
(Vector Laboratories) for 10 minutes each and blot dried in between. Sections were incubated 852 
for 60 minutes with primary antibody diluted in TBS pH7.6 (see Supplementary Table 20 for 853 
antibody details). Slides were washed twice in TBS pH7.6 for 5 minutes each before 854 
incubation for 30 minutes with the secondary antibody supplied with the kit. Slides were 855 
washed twice in TBS pH7.6 for 5 minutes each, and developed using peroxidase chromogen 856 
DAB. Sections were counterstained in Mayer’s Haematoxylin for 30 seconds, washed and 857 
put in scots tap water for 30 seconds. Slides were dehydrated through graded ethanol (70% to 858 
99%) and then placed in Xylene prior to mounting with DPX (Sigma-Aldrich).  Sections 859 
were imaged on a Nikon Eclipse 80i microscope using NIS-Elements Fv4. 860 
Alignment, quantification and quality control of scRNA-seq data  861 
Droplet-based (10x) sequencing data was aligned and quantified using the Cell Ranger 862 
Single-Cell Software Suite (version 2.0.2, 10x Genomics Inc) using the GRCh38 human 863 
reference genome (official Cell Ranger reference, version 1.2.0).  Smart-seq2 sequencing 864 
data was aligned with STAR (version 2.5.1b), using the STAR index and annotation from the 865 
same reference as the 10x data.  Gene-specific read counts were calculated using htseq-count 866 
(version 0.10.0).  Cells with fewer than 200 detected genes and for which the total 867 
mitochondrial gene expression exceeded 20% were removed.  Genes that were expressed in 868 
fewer than 3 cells were also removed.  We detected on average ~3,000 genes per cell with the 869 
10x Genomics platform and ~6,000 genes with the Smart-seq2 protocol. 870 
   871 
Doublet detection  872 
Doublets were detected with an approach adapted from Pijuan-Sala et al.56. In the first step of 873 
the process, each 10X lane was processed independently. Scrublet57 was run, obtaining per-874 
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cell doublet scores. The standard Seurat-inspired Scanpy processing pipeline was performed 875 
up to the clustering stage, using default parameters. Each cluster was subsequently separately 876 
clustered again, yielding an over clustered manifold, and each of the resulting clusters had its 877 
Scrublet scores replaced by the median of the observed values. The resulting scores were 878 
assessed for statistical significance, with p-values computed using a right-tailed test from a 879 
normal distribution centred on the score median and a MAD-derived standard deviation 880 
estimate. The MAD was computed from above-median values to circumvent zero-truncation. 881 
The p-values were FDR-corrected with the Benjamini-Hochberg procedure, and a 882 
significance threshold of 0.1 was imposed. In the second step of the process, all 10X lanes for 883 
a single tissue were pooled together and the Seurat-inspired Scanpy processing was repeated, 884 
with the addition of Harmony58 with a theta of 3 for batch correction between the lanes 885 
before the neighbour graph identification step. The joint manifold was clustered, and the 886 
frequency of identified doublets was computed. The same statistical framework as in the first 887 
step was used to identify clusters significantly enriched in doublets, which were subsequently 888 
flagged as doublets in their entirety and removed. 889 
 890 
Clustering and annotation 891 
Downstream analysis included data normalisation (NormalizeData, LogNormalize method, 892 
scaling factor 10000), data feature scaling (ScaleData), variable gene detection 893 
(FindVariableGenes), PCA (RunPCA, from variable genes) and Louvain graph-based 894 
clustering (FindClusters, data dimensionality reduction using PCA, clustering resolution 895 
(res.30)) performed using the R package Seurat (version 2.3.4). Cluster cell identity was 896 
assigned by manual annotation using known marker genes and computed differentially 897 
expressed genes (DEGs) using FindAllMarkers function in Seurat package (one-tailed 898 
Wilcoxon rank sum test, p-values adjusted for multiple testing using the Bonferroni 899 
correction; Supplementary Table 3).  For computing DEGs all genes were probed provided 900 
they were expressed in at least 25% of cells in either of the two populations compared and the 901 
expression difference on a natural log scale was at least 0.25.  Manual annotation was 902 
performed iteratively, which included validating proposed cell labels with known markers 903 
and further investigating clusters whose gene signatures indicated additional diversity. 904 
Number of each cell type per sample, annotations per cell, and nGene and nUMI per cell type 905 
are reported in Supplementary Tables 4, 5, 8 and 9, respectively. 906 
 907 
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Clustering and cell type assignment for fetal liver data was assessed using two additional 908 
clustering methods (not shown): Agglomerative clustering (with Ward linkage and Euclidean 909 
affinity) and Gaussian mixture (AgglomerativeClustering class from cluster module and 910 
GaussianMixture from mixture module in sklearn version 0.19.1 Python 3.6.3).  Consensus 911 
agreement between the 3 clustering methods was measured by Rand index and adjusted 912 
mutual information implemented in the metrics module in sklearn package.  The Rand Index 913 
scores were 0.89 and 0.85 for Agglomerative and Gaussian Mixture clustering methods 914 
respectively. 915 
 916 
After annotation was completed, a cell type classifier was built by training an SVM on 917 
labelled fetal liver scRNA-seq data with grid search for parameter optimization based on 918 
training data. 70% of the data was used for training and the other 30% for test. The SVM was 919 
previously compared in terms of accuracy and recall with a random forest and logistic 920 
regression classifiers trained on the same data. Out of the 3 classifiers the SVM was chosen 921 
due to showing a mean accuracy and weighted mean recall of 95%. Random forest showed 922 
89% for both precision and recall (Supplementary Table 11).  The SVM classifier was used 923 
for automatic annotation of the Smart-seq2 and mini bulk RNA sequencing data sets to allow 924 
identification of biologically meaningful clusters and DEG computation.  925 
 926 
Data generated from fetal skin, kidney and yolk sac was pre-processed, normalised, clustered 927 
and manually annotated, in parallel with, and using the same pipeline as, the liver data. 928 
Annotation by cell type for skin and kidney, and yolk sac are reported in Supplementary 929 
Tables 6 and 7, respectively.  Skin and kidney data were combined using the MergeSeurat 930 
function. Clusters characterised by differentially expressed immune gene markers were 931 
extracted from the NLT dataset for subsequent comparative analysis with liver-derived 932 
immune populations.  Human cord blood and adult bone marrow datasets were downloaded 933 
from Human Cell Atlas data portal (https://preview.data.humancellatlas.org/).  These were 934 
processed using the same approach as described above, followed by manual annotation.  935 
Decidua and placental data from Vento-Tormo et al.16, were downloaded from ArrayExpress 936 
record E-MTAB-6701 (https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-6701/). 937 
 938 
Data integration 939 
We used Harmony data integration58 to correct for batch effect between sample identities.  940 
The average kBET rejection rate statistically significantly improved from 0.735 to 0.471 941 
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(Supplementary Table 13) following Harmony data integration (p-value 3.83e-3 in 942 
Kolmogorov–Smirnov test and p-value 8.8e-6 in Wilcoxon signed-rank test).   The manifold 943 
was subjected to re-clustering using Harmony adjusted PCs with parameters as mentioned 944 
above in “Clustering and annotation”. Cell type classifications were then ascertained through 945 
re-annotation of the clusters derived from Harmony adjusted PCs to produce the final 946 
annotation. 947 
 948 
Changes in cell proportions over development 949 
Comparison of cell proportions across gestational stages was assessed by modelling cell 950 
number data with negative binomial regression based on Poisson-gamma mixture 951 
distribution. Cell numbers were corrected for CD45-/CD45+ FACS sorted ratio 952 
(Supplementary Table 1) prior to applying negative binomial regression modelling. 953 
Modelling was achieved using the glm.nb function in the R MASS package. Modelled cell 954 
number data were studied for regression coefficient significance (variable coefficient p-value 955 
≤ 0.05) to the response variable of gestational age with the corresponding z-score and p-956 
values taken (Supplementary Table 10) 957 
 958 
Dimensionality reduction and trajectory analysis 959 
Dimensionality reduction methods included tSNE (Seurat, computed from the first 20 PCs, 960 
Barnes-Hut fast computation), UMAP (Python UMAP package, 5 nearest neighbours, 961 
correlation metric, minimum distance 0.3, computed from the first 20 PCs), FDG 962 
(ForceAtlas2 class from fa2 Python Package, Barnes-Hut implementation for faster 963 
computation with theta 0.8, 2000 iterations) and partition-based approximate graph 964 
abstraction (PAGA) (paga in scanpy Python package version 1.2.2).  Development 965 
trajectories were inferred by comparing FDG, PAGA and diffusion map plots.  Inferred 966 
trajectory analysis included computing diffusion map (scanpy tl.diffmap with 20 967 
components), pseudotime (scanpy tl.dpt setting the earliest known cell type as root) and 968 
variable genes across pseudotime. Order of cells in pseudotime was statistically significant 969 
using Kruskal-Wallis test (p < 1x10-7).   970 
 971 
Comparisons of trajectories across stage were performed by subsetting liver dataset by stage 972 
using SubsetData function, computing dimensional reduction coordinates, batch correcting 973 
by sample using Harmony, and plotting PAGA and FDG by stage.  Cell type comparisons 974 
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across tissue involved subsetting for cell types of interest using SubsetData function, merging 975 
cross-tissue datasets using MergeSeurat function, and processing data using the same 976 
approach as for the liver and NLT datasets.  Harmony batch correction was then performed 977 
by tissue type, with results presented as combined UMAPs, FDGs and PAGA score 978 
heatmaps. 979 
 980 
Dynamically expressed genes across pseudotime 981 
Genes that vary across pseudotime were calculated using DifferentialGeneTest function in 982 
Monocle in R (version 2.6.4) and a cut-off of adjusted p-value < 0.001 applied. This was 983 
applied on the entire pseudotime range and also on the pseudotime intervals specific to each 984 
cell type in order to avoid limitation to the genes characterised by monotonic changes across 985 
the inferred trajectory.  Expression of pseudotime variable genes were min-max normalised 986 
prior to visualization and annotated based on each gene’s involvement in relevant cell-987 
specific functional modules or hallmark functional pathways from MSigDB v6.2, a curated 988 
molecular signature database59. Peak expression for each gene over pseudotime was 989 
calculated and grouped into ‘Early’, ‘Mid’ or ‘Late’ categories. For visualisation purposes, 990 
the resulting gene lists were minimised by ordering them from those present in the most 991 
selected functional pathways to least, as well as ensuring coverage across pseudotime.  These 992 
genes were manually compared against current literature to determine if they have known 993 
functional or cell type associations.  The top 20-25 genes in each list were displayed using the 994 
ggplot2 package.  Transcription factors were marked within the dataset based on 995 
AnimalTFDB transcription factor prediction database60. The full pseudotime gene list is 996 
available in the interactive files accompanying diffusion maps.   997 
 998 
 999 
Visualisation by animated force-directed graph representation 1000 
The FDG animation was created using an in-house modified version of the ForceAtlas2 class 1001 
in fa2 Python package by saving all the intermediate states (published version only outputs 1002 
the final state and discards all intermediates).  The FDG coordinates at each iteration were 1003 
plotted and the resulting graphs were assembled in a mp4 video format using VideoWriter in 1004 
cv2 (version 3.3.1) Python package.  1005 
 1006 
Differential gene extraction and validation 1007 
31 
Differential gene validation was done using a random forest classifier 1008 
(RandomForestClassifier class in ensemble module of sklearn Python package v0.19.1, with 1009 
500 estimators, min_sample_split of 5, class weights set to the “balanced” policy and all 1010 
other parameters set to default).  The Random Forest algorithm was chosen as it resembled 1011 
the FACS gating hierarchy. 70% of the data was used for training and 30% for test. 1012 
Parameter tuning was performed on training data using grid search. To determine whether 1013 
tissue-related transcriptome variations were present in equivalent immune populations 1014 
between liver, skin and kidney, each equivalent population was taken in turn and grouped 1015 
according to its tissue of origin. Seurat FindMarkers function was then applied in a pair-wise 1016 
manner between each tissue subset to produce a cell type-specific list of genes marking each 1017 
tissue subset. These were investigated in turn for biological relevance, with representative 1018 
genes displayed using VlnPlot function of Seurat. 1019 
 1020 
DEGs from B cell pseudotime were studied for significant expression change across stage 1021 
and differentiation state using a one-way ANOVA with Tukey’s multiple comparison test. 1022 
DEGs displaying significant variance in ln-normalised expression were further studied for 1023 
correlation to DEGs identified within all other cell-types across stage. B cell pseudotime 1024 
DEGs with significantly correlated trends of expression to DEGs within other cell-types 1025 
across stage (p-value <0.05, Two-tailed Pearson’s R at 95% CI) were plotted in Prism 1026 
(v8.1.2, GraphPad Software).  All graphs presented in the manuscript were plotted using 1027 
ggplot2 R package, Seurat implementation of ggplot2, matplotlib Python package, Prism 1028 
(v.8.1.2, GraphPad Software) or FlowJo (v10.4.1). Spot plots are shown throughout the 1029 
manuscript, displaying scaled expression of ln-normalised counts.  1030 
 1031 
 1032 
 1033 
Primary immunodeficiency (PID) gene list curation 1034 
Disease and genetic deficiency information was extracted from Picard et al.8 and manually 1035 
annotated to include HGNC symbol names for each disease-associated genetic defect for 1036 
subsequent correlation with the liver dataset.  Diseases implicated in PID were divided 1037 
according to the International Union of Immunological Societies (IUIS) major categories and 1038 
screened across the liver scRNA-seq dataset.  315 unique genes were identified in the dataset 1039 
from the 354 inborn errors of immunity highlighted in the article.  For each disease category 1040 
a dot plot was generated using Seurat DotPlot function and ordered by highest expression 1041 
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across each gene and across each cell type, highlighting those cell types in each disease 1042 
category which express the highest number of genes associated with a genetic defect. 1043 
 1044 
CellPhoneDB analysis 1045 
CellPhoneDB v2.0 (www.cellphonedb.org)61 was used for the receptor-ligand analysis in 1046 
Figure 3d. Significant (p < 0.05) receptor-ligand interactions between VCAM1+ 1047 
Erythroblastic Island macrophages and the two erythroid (early and mid) populations were 1048 
displayed. 1049 
 1050 
Whole genome sequencing and fetal cell identification 1051 
To identify maternal cells present in our data we combined the information from fetal whole 1052 
genome DNA sequencing with the single cell RNA-seq data. For each sample we measured 1053 
the allele frequency in the fetal DNA of SNPs from the 1000 genomes project62 falling within 1054 
exons with a population allele frequency in excess of 1%.  We then consider only those SNPs 1055 
which are homozygous in the fetal DNA for follow up in the scRNA-seq data.  A SNP was 1056 
considered to be homozygous if its allele frequency in the fetal DNA was less than 0.2 or 1057 
greater than 0.8 and had an FDR adjusted p-value of less than 0.01 under a binomial test for 1058 
the null hypothesis that the allele frequency in the DNA was in the range [0.3,0.7].  1059 
  1060 
The allele frequency of each of these SNPs with population allele frequency > 1% that are 1061 
known to be homozygous in the fetal DNA was then measured in each cell in the scRNA-seq 1062 
data.  Any deviations from homozygosity in the RNA-seq data must be a consequence of 1063 
either sequencing errors, RNA editing, or the genotype of the cell differing from the fetal 1064 
DNA.  For each cell, we calculated the total fraction of reads at the SNPs (selected as 1065 
described above) that differ from the fetal genotype.  We then assume that the genome-wide 1066 
rate of deviations due to sequencing errors and RNA editing is less than or equal to 2%.  For 1067 
maternal cells, the expected genome wide rate of deviation at these SNPs is equal to half the 1068 
mean of the population allele frequency at the interrogated SNPs.  Finally, for each cell we 1069 
calculated the posterior probability of the cell being fetal or maternal assuming a binomial 1070 
distribution with rate 2% for a fetal cell and half the mean of the population allele frequency 1071 
for the maternal cell and assign a cell as: maternal/fetal if either posterior probability exceeds 1072 
99%, ambiguous otherwise.  We validated this method using samples for which both the fetal 1073 
and maternal DNA were available. 1074 
 1075 
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‘Hyperion’ Imaging mass cytometry (IMC) 1076 
Antibodies were conjugated to metals using the Fluidigm MaxPar conjugation kits and the 1077 
associated method with following modifications; the lanthanides were used at 1.5 mM and 1078 
washed for a shorter duration (4x 5 minutes) in W buffer in prior to elution. Ultrapure MilliQ 1079 
water was used throughout for any dilutions and washes. 4 µm Formalin-fixed paraffin-1080 
embedded sections obtained from 8 and 15 PCW fetal liver tissue blocks were incubated at 1081 
60 °C for 1 hour then dewaxed in Xylene (Fisher). After rehydration through graded alcohols 1082 
(Fisher) and a 5 minute wash in water, the sections were subjected to Heat-Induced Epitope 1083 
Retrieval with Citrate buffer (pH- 6.0).  Sections were then washed in water and PBS (Gibco) 1084 
and blocked with 3% BSA (Sigma-Aldrich) for 45 minutes. A mixture of 8 metal-conjugated 1085 
antibodies diluted in 0.5% BSA (see Supplementary Table 21 for antibody details, was added 1086 
to the sections for overnight incubation at 4 °C in a humidified chamber. Slides were washed 1087 
twice in 0.2% Triton X-100 diluted in PBS for 8 minutes and then twice in PBS for 8 1088 
minutes. 1089 
 1090 
To counterstain nucleated cells, sections were incubated with 312.5nm (193 Ir) Intercalator-Ir 1091 
(Fluidigm) for 30 minutes at room temperature. Slides were then washed in water for 5 1092 
minutes, and allowed to air-dry at room temperature prior to imaging on the Hyperion 1093 
imaging mass cytometer. Using expected target cell frequencies from previous fluorescence 1094 
flow cytometry data, Region of Interest (ROI) size was set to 2.8mm by 3.8mm. The ablation 1095 
energy was set at 2 db with a laser frequency of 200Hz. Each session of ablation generated a 1096 
.MCD image file containing information for every panorama and ROI measured whereby 1097 
each 1µm piece of tissue liberated by the laser was analysed for ionic content on a per 1098 
channel basis by Time of Flight.  Single cell segmentation and feature extraction was 1099 
performed using CellProfiler (v3.1.5). Nuclei were identified using the 1100 
“IdentifyPrimaryObjects” module where the input images were the sum of the DNA stained 1101 
Iridium channels (191 and 193) constructed by the “ImageAfterMath” module.  The diameter 1102 
range set for Nuclei identification was 4-15 pixel units.  The “ExpandOrShrink” module was 1103 
used to grow the nuclear segmentation area by 3 pixels to define the cellular area and the 1104 
“MeasureObjectIntensity” module was used to determine the mean intensity for each cell 1105 
object identified.   1106 
 1107 
Light sheet fluorescence microscopy  1108 
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Male embryos at 5, 7 and 11 PCW deemed devoid of morphological anomalies were 1109 
dissected after overnight fixation in 4% PFA. Whole-mount and cryosection immunostaining 1110 
were performed as described in Belle et al.63, with the following conditions: tissue was 1111 
incubated with primary antibodies (see Supplementary Table 22 for antibody details) for 9 1112 
days at 37°C, with secondary antibody for 16 hours at 37°C using dedicated host species 1113 
antibodies and reagent combination. TO-PRO-3 647 was used at 1:100 in whole embryos and 1114 
1:5000 on cryosections. Whole-mount specimens were solvent-cleared as described63, and 1115 
imaged in dibenzylether with a Miltenyi Lavision Biotech ultramicroscope (Olympus 1116 
MXV10 stereomicroscope and PCO Edge SCMOS CCD camera using the dedicated 1117 
Imspector pro acquisition software. Four lasers (at 488, 561, 647 and 790nm wavelengths) 1118 
were used to generate light sheets. IMaris (v9.2, BitPlane) was used for image conversion and 1119 
processing. Photoshop (Adobe) was used to create panels. All raw files are being made 1120 
available on demand through our dedicated KeenEye Technologies-hosted Platform 1121 
(www.transparent-human-embryo.com, <<request database access>>). 1122 
 1123 
Statistics and reproducibility 1124 
For all analyses of fetal liver 3’ 10x data, n = 14 biologically independent samples were 1125 
included. This includes Figure 1b, Figure 2a, Figure 3a-c, Figure 4b-c, Figure 5a-b, Figure 1126 
6a-b, Figure 6g, Extended Data 1c, Extended Data 2a, Extended Data 3a-e, Extended Data 1127 
4a, Extended Data 5e, Extended Data 5g-h, Extended Data 6a-e, Extended Data 7b and h, and 1128 
Extended Data 8. 1129 
For all analyses of fetal liver 3’ 10x data by developmental stage, n = 4 7-8 PCW, n = 4 9-11 1130 
PCW, n = 3 12-14 PCW, and n = 3 15-17 PCW biologically independent samples were used. 1131 
This includes Figure 1c, Figure 4a, Extended data 1d-e, Extended Data 5a-c, and Extended 1132 
Data 5f. 1133 
For analyses including 10x sequencing data of skin, kidney, yolk sac, decidua and placenta, n 1134 
= 7, 3, 3, 11 and 5 biologically independent samples were used, respectively. These analyses 1135 
are shown in Figure 3b-c, Figure 4b-c, Figure 5a-b, Figure 6g, Extended Data 1a-b, Extended 1136 
Data 3c-e, Extended Data 5g-h, and Extended Data 6c-e. 1137 
For analysis including sequencing data of cord blood and adult bone marrow, n = 8 1138 
biologically independent samples of each were used. These analyses are shown in Figure 6g 1139 
and Extended Data 7h. 1140 
 1141 
35 
For all scRNA-seq data shown, all cells of a given label from indicated tissues are shown, no 1142 
down-sampling or sub-setting was performed. The following cells numbers generated using 1143 
scRNA-seq are displayed in each of the listed figures: 1144 
Figure 1b-c 113,063 fetal liver cells 1145 
Figure 2a 113,063 fetal liver cells 1146 
Figure 3a 104,515 fetal liver cells 1147 
Figure 3b 43,507 fetal liver cells, 2,455 yolk sac cells, and 243 skin cells 1148 
Figure 3c 52,327 fetal liver cells, 362 skin cells, 28 kidney cells, and 2,793 yolk sac cells 1149 
were analysed, and a maximum of 20 cells displayed of each cell type per 1150 
tissue 1151 
Figure 4a 16,919 fetal liver cells 1152 
Figure 4b 16,919 fetal liver cells, 2,757 skin cells, 213 kidney cells, and 259 yolk sac 1153 
 cells 1154 
Figure 4c 6,706 NK cells and 1,726 ILC precursors from fetal liver, 1,479 NK cells and 1155 
1,142 ILC precursors from skin, and 155 NK cells and 36 ILC precursors from 1156 
kidney 1157 
Figure 5a-b 38,464 fetal liver cells, 6,887 yolk sac cells, and 10,008 cells from decidua 1158 
and placenta 1159 
Figure 6a-b 5,673 fetal liver cells 1160 
Figure 6g 3,439 fetal liver HSC/MPP, 205 yolk sac progenitors, 1,082 cord blood HSCs, 1161 
and 3,668 adult bone marrow HSCs   1162 
Ext Data 1a 10,258 skin cells, and 17, 95 kidney cells 1163 
Ext Data 1b 10,071 yolk sac cells 1164 
Ext Data 1c-e 113,063 fetal liver cells 1165 
Ext Data 1f 1,206 fetal liver cells from n = 2 biologically independent samples profiled 1166 
using Smart-seq2 (also displayed in Extended Data 2b) 1167 
Ext Data 2a 113,063 fetal liver cells 1168 
Ext Data 2b 1,206 fetal liver cells from n = 2 biologically independent samples profiled 1169 
using Smart-seq2; and 381 fetal liver erythroid liver erythroblastic island (EI) 1170 
populations (early, mid and late erythroids, VCAM1+ EI macrophages), 1171 
Kupffer cells and endothelium validated by SS2 from n = 2 biologically 1172 
independent fetal liver samples 1173 
36 
Ext Data 2d 381 fetal liver erythroid liver erythroblastic island (EI) populations (early, mid 1174 
and late erythroids, VCAM1+ EI macrophages), Kupffer cells and endothelium 1175 
validated by SS2 from n = 2 biologically independent fetal liver samples 1176 
Ext Data 3a-b 52,237 fetal liver cells 1177 
Ext Data 3c 52,237 fetal liver cells, 362 skin cells, and 28 kidney cells 1178 
Ext Data 3d 52,237 fetal liver cells, 362 skin cells, 28 kidney cells, and 2,588 yolk sac cells 1179 
Ext Data 3e 3,439 HSC/MPP, 1,342 MEMP, 11,985 Early Erythroid, 27,000 Mid 1180 
Erythroid, 3,180 Late Erythroid, 3,983 Megakaryocytes, and 1,308 Mast cells 1181 
from fetal liver; 55 MEMP, 51 Mid Erythroid, 137 Late Erythroid, 11 1182 
Megakaryocytes, and 108 Mast cells from skin; and 2 MEMP and 26 1183 
Megakaryocytes from kidney. 1184 
Ext Data 5a 16,919 fetal liver cells 1185 
Ext Data 5b-c 767 fetal liver Early lymphoid/T lymphocytes 1186 
Ext Data 5d 16,666 fetal liver cells from n = 7 biologically independent samples. 1187 
Ext Data 5e 7,467 fetal liver cells 1188 
Ext Data 5f 32,308 fetal liver cells 1189 
Ext Data 5g 16,919 fetal liver cells, 2,775 skin cells, 213 kidney cells, and 464 yolk sac 1190 
cells 1191 
Ext Data 5h 1,726 fetal liver ILC precursors, 1,142 skin ILC precursors, and 36 kidney 1192 
ILC precursors 1193 
Ext Data 6a 6,606 fetal liver cells 1194 
Ext Data 6b  11,653 fetal liver cells  1195 
Ext Data 6c 38,646 fetal liver cells, 6,887 yolk sac cells, and 10,008 cells from decidua 1196 
and placenta were analysed, and a maximum of 50 cells displayed of each cell 1197 
type per tissue 1198 
Ext Data 6d 43,498 fetal liver cells, 8,350 skin cells, and 1,514 kidney cells 1199 
Ext Data 6e 24,841 Kupffer cells, 2,586 monocytes, 253 pDC precursors, 336 DC1, and 1200 
3,954 DC2 from fetal liver; 5,474 macrophages, 704 monocytes, 36 pDCs, 99 1201 
DC1, and 527 DC2 from skin; and 1,075 macrophages, 82 monocytes, 1 pDC, 1202 
1 DC2, and 271 DC2 from kidney 1203 
Ext Data 7b 6,606 fetal liver cells and 161 of 349 scRNA-seq profiled cells 1204 
(Supplementary Table 12) from n = 3 biologically independent samples, 1205 
sorted as per FACS gates in Extended Data 7a 1206 
37 
Ext Data 7h 3,439 HSC/MPPs, 1,341 MEMPs, 234 Pre pro B cells, 658 Neutrophil-1207 
myeloid progenitors, 350 Monocyte precursors, 253 pDC precursors, and 330 1208 
DC precursors from fetal liver; 205 yolk sac progenitors; 1,082 cord blood 1209 
HSCs; and 3,668 adult bone marrow HSCs  1210 
Ext Data 8 113,063 fetal liver cells 1211 
 1212 
 1213 
Representative mini bulk RNA-seq data of 100 cells per cell state from 1 of n = 3 biologically 1214 
independent fetal liver samples is shown in Extended Data 2b-c. 1215 
 1216 
Cytospin images shown in Figure 2b and Extended Data 5e are representative from 1 of n = 3 1217 
biologically independent samples. 1218 
 1219 
Hyperion images shown in Figure 2c are representative from 1 of n = 4 biologically 1220 
independent 8 PCW fetal livers and 1 of n = 4 biologically independent 15 PCW fetal livers. 1221 
 1222 
Immunohistochemical (IHC) staining of 8 PCW fetal skin in Figure 3d is representative from 1223 
1 of n = 3 biologically independent samples. IHC staining of fetal liver in Extended Data 4-b 1224 
are from independent samples and both are representative from 1 of n = 3 biologically 1225 
independent samples. 1226 
 1227 
Light sheet fluorescence microscopy of embryo (5PCW) hand skin shown in Figure 3e is a 1228 
representative image from 1 of n = 3 biologically independent samples. 1229 
 1230 
Statistical analysis of differential gene expression was done using one-tailed Wilcoxon rank 1231 
sum test with Bonferroni correction, including those shown in heatmaps and violin plots.  1232 
Statistically significant gene expression shown in Figure 4c comparing expression in NK 1233 
cells and ILC precursors across tissues was p < 0.001 where **** was shown, and p = 1234 
0.00236 for TXNIP expression in ILC precursors in liver compared to those in kidney.  1235 
In Figure 6b, expression of genes in HSC/MPP 1 compared to each other cell cluster, and 1236 
MEMP/neutrophil-myeloid progenitor/pre pro B cell compared to each other cell cluster was 1237 
statistically significant unless specified as not significant (ns). All p < 0.001, except 1238 
expression of KLF1 between HSC/MPP1 vs HSC/MPP2 (p = 0.00934), IL1RL1 between 1239 
HSC/MPP 1  vs HSC/MPP 2 (p = 0.00148), GATA2 between MEMP vs HSC/MPP2 (p = 1240 
38 
0.00802), BCL11A between HSC/MPP 1 vs HSC/MPP 7 (p = 0.00114), LYZ between 1241 
HSC/MPP 1 vs HSC/MPP 5 (p = 0.00675), AZU1 between HSC/MPP 1 vs HSC/MPP 8 (p = 1242 
0.00494), CSF1R between Neutrophil-myeloid progenitors vs HSC/MPP 8 (p = 0.213). In 1243 
Figure 6g, **** indicates p < 0.0001 when comparing expression of ANXA1, DUSP1, HLA-1244 
B, and HSPAIA between samples. Expression of genes in fetal liver Early lymphoid/T 1245 
lymphocytes was compared across developmental stages and displayed in Extended Data 5b-1246 
c. No significant difference across stage was observed in the genes displayed in Extended 5b. 1247 
The following comparisons shown in Extended Data 5c were significant: CD2 expression at 1248 
7-8 PCW vs 9-17 PCW (p < 0.0001) and vs 12-17 PCW (p < 0.0001); TRDC expression at 7-1249 
8 PCW vs 9-17 PCW (p < 0.0001) and 9-11 PCW vs 12-17 PCW (p < 0.0001); CD8A 1250 
expression at 7-8 PCW vs 9-17 PCW (p  = 0.00714); CD27 expression at 7-8 PCW vs 9-17 1251 
PCW (p < 0.0001) and 9-11 PCW vs 12-17 PCW (p < 0.0001); IL7R expression at 7-8 PCW 1252 
vs 9-17 PCW (p < 0.0001), 9-11 PCW vs 12-17 PCW (p = 0.00168), and 12-14 PCW vs 15-1253 
17 PCW (p = 0.00216); JCHAIN expression at 7-8 PCW vs 9-17 PCW (p < 0.0001); CD3D 1254 
expression at 7-8 PCW vs 9-17 PCW (p < 0.0001); KLRB1 expression at 9-11 PCW vs 12-17 1255 
PCW (p < 0.0001); TRAC expression at 7-8 PCW vs 9-17 PCW (p < 0.0001) and 9-11 PCW 1256 
vs 12-17 PCW (p < 0.0001); and PRF1 expression at 9-11 PCW vs 12-17 PCW (p < 0.0001). 1257 
Expression of genes in ILC precursors in fetal liver, skin and kidney, as shown in Extended 1258 
Data 5h, was compared between tissues and no significant difference was observed. Extended 1259 
Data 6e shows comparisons between fetal liver, skin and kidney for macrophages, 1260 
monocytes, pDCs, DC1, and DC2. The following comparisons were statistically significant 1261 
(p < 0.0001) between macrophages from different tissues: CD14 expression in kidney vs liver 1262 
and vs skin; CD68 expression in liver vs skin and vs kidney; CD163, RNASE1 and F13A1 1263 
expression between all tissues; and, VCAM1 expression in liver vs skin and vs kidney. The 1264 
following comparisons were statistically significant between monocytes from different 1265 
tissues:  CD14 expression in liver vs skin (p < 0.0001); CD68 expression in liver vs skin (p < 1266 
0.0001); S100A9 expression in liver vs kidney (p < 0.0001), and skin vs kidney (p = 0.0245); 1267 
FCGR3A. expression in liver vs skin (p = 0.0004); POSTN expression in liver vs skin (p < 1268 
0.0001) and vs kidney (p < 0.0001), and skin vs kidney (p = 0.0411). No significant 1269 
difference was observed when comparing genes in pDCs across tissues. CLEC9A expression 1270 
was statistically significantly different in liver vs skin DC1 (p < 0.0001). The following 1271 
comparisons were statistically significant between DC2 from different tissues:  CD1C 1272 
expression in skin vs liver (p < 0.0001) and vs kidney (p < 0.0001); CLEC10A expression in 1273 
kidney vs liver (p < 0.0001). and vs skin (p < 0.0001); S100B expression in skin vs liver (p < 1274 
39 
0.0001) and vs kidney (p = 0.0162); and FCER1A and CD83 expression between each tissue 1275 
(p < 0.0001). 1276 
 1277 
Statistical analysis of HSC colony assays shown in Figure 6c-e, and Extended Data 7 was 1278 
done by applying two-tailed Fisher’s exact tests to colony counts. Figure 6c and d, and 1279 
Extended Data 7f shows 125, 217 and 124 colonies from 7-8 PCW, 12-14 PCW and 15-17 1280 
PCW fetal liver samples, respectively from n = 2 biologically independent samples per 1281 
development stage. The number of colonies per sample is 93, 32, 93, 124, 84, 40, which are 1282 
shown in Extended Data 7c.  The number of colonies between the following stages in Figure 1283 
6c were statistically significant: Erythroid colonies in 7-8 PCW vs. 15-17 PCW (p = 0.0238), 1284 
Erythroid/Megakaryocyte/Myeloid colonies in 7-8 PCW vs. 15-17 PCW (p = 0.0294), NK 1285 
colonies in 7-8 PCW vs. 15-17 PCW (p = 0.0357), and Erythroid/Myeloid colonies in 7-8 1286 
PCW vs 12-14 PCW (p = 0.0188) and 15-17 PCW (p < 0.001), and 12-14 PCW vs 15-17 1287 
PCW (p = 0.0232). The number of Erythroid-containing colonies was significant between 1288 
each stage shown in Figure 6d (p < 0.001). The number of colonies that differentiated along 3 1289 
lineages was significant between 7-8 PCW vs 12-14 PCW (p = 0.0041), and 7-8 PCW vs 15-1290 
17 PCW (p = 0.0027).  Figure 6e shows 141, 74 and 124 colonies from 7-8 PCW, 12-14 1291 
PCW and 15-17 PCW fetal liver samples, respectively from n = 2 biologically independent 1292 
samples per development stage. The number of B cell-forming colonies in Figure 6e was 1293 
significant between 7-8 PCW vs 12-14 PCW (p = 0.0014) and 15-17 PCW (p = 0.0044). 1294 
Extended Data 7d-e shows 163, 196, 182 colonies from n = 3 7-8 PCW, n = 2 12-14 PCW, 1295 
and n = 2 15-17 PCW biologically independent fetal liver samples, respectively on the left, 1296 
and 42, 74, 47, 97, 99, 59, 123 colonies by individual sample on the right. The number of 1297 
Erythroid colonies compared to all other types shown in Extended Data 7d was statistically 1298 
significant between 12-14 PCW and 15-17 PCW (p = 0.0307). The number of Erythroid-1299 
containing colonies was significant between 7-8 PCW vs 15-17 PCW (p = 0.0013), and 12-14 1300 
PCW vs 15-17 PCW (p = 0.0497), as shown in Extended Data 7e. Extended Data 7f shows 1301 
125, 217 and 124 colonies from 7-8 PCW, 12-14 PCW and 15-17 PCW fetal liver samples, 1302 
respectively from n = 2 biologically independent samples per development stage. Extended 1303 
Data 7g shows 141, 74 and 124 colonies from 7-8 PCW, 12-14 PCW and 15-17 PCW fetal 1304 
liver samples, respectively from n = 2 biologically independent samples per development 1305 
stage. The percentage of NK-containing colonies was statistically significant in 7-8 PCW vs 1306 
15-17PCW (p = 0.0032), and 12-4 PCW vs 15-17 PCW (p = 0.0115).  1307 
 1308 
40 
Flow cytometric analysis of cell cycle phases, as shown in Figure 6g and Extended Data 7i 1309 
was performed on cells from n = 3 7-8 PCW and n = 3 12-16 PCW biologically independent 1310 
fetal liver samples, and n = 2 biologically independent cord blood samples. One-way 1311 
ANOVA with Tukey’s multiple comparison test was used to determine statistical significance 1312 
between stages (7-8 PCW and 12-14 PCW) and samples (fetal liver and cord blood). The 1313 
percent of CD34+CD38- cells in G0 was significantly higher in 12-14 PCW livers compared 1314 
to 7-8 PCW livers (p = 0.0136).  1315 
 1316 
Cell cycle phases determined by transcriptome analysis of fetal liver cells, fetal skin cells, 1317 
and fetal kidney cells is shown in Extended Data 3e. Statistical significance of the proportion 1318 
of MEMP and Megakaryocytes in each cell cycle phase was compared between fetal liver, 1319 
skin and kidney using Kruskal-Wallis with Dunn’s post hoc test. Statistical significance of 1320 
the proportion of Mid and Late Erythroids, and Mast cells in each cell cycle phase was 1321 
compared between fetal liver and skin using two-tailed Mann-Whitney tests. The following 1322 
comparisons were statistically significant: Megakaycoytes in fetal liver vs fetal kidney in G1 1323 
(p = 0.0317), G2M (p = 0.0317) and S (p = 0.0139); Megakaryocytes in fetal liver vs fetal 1324 
skin in S (p = 0.0039); Mid Erythroids in fetal liver vs skin in G1 (p = 0.0031) and G2M (p < 1325 
0.0001); Late Late Erythroids in fetal liver vs fetal skin in G1 (p = 0.0021) and S (p < 1326 
0.0001); and, Mast cells in fetal liver vs fetal skin in G1 (p = 0.0248) and S (p = 0.0337). 1327 
 1328 
Statistical comparison of the percent of MEMP, Mid and Late Erythroids, Megaryocytes and 1329 
Mast cells expressing MKI67 in fetal liver vs NLT (skin and kidney) was performed using 1330 
two-tailed Mann-Whitney tests. This is displayed in Extended Data 3e, where the following 1331 
comparisons were statistically significant: Megakaryocytes in fetal liver vs fetal NLT (p = 1332 
0.007), Mid Erythroid in fetal liver vs fetal skin (p = 0.0305), and Late Erythroid in fetal liver 1333 
vs fetal skin (p = 0.0368). 1334 
 1335 
Statistical comparison of the percent of fetal liver HSC/MPP expressing MKI67 compared to 1336 
the percent of fetal liver MEMP, Pre pro B cells, Neutrophil-myeloid progenitors, Monocyte 1337 
precursors, pDC precursors and DC precursors, Yolk Sac progenitors, and HSC from cord 1338 
blood and adult bone marrow expressing MKI67 was performed using Kruskal-Wallis with 1339 
Dunn’s post hoc test.  This is displayed in Extended Data 7h, where the percent of MKI67-1340 
expressing fetal liver HSC/MPPs was statistically significant when compared to the following 1341 
populations: fetal liver MEMP (p = 0.0180), Monocyte precursors (p < 0.0001), DC 1342 
41 
precursors (p < 0.0001), cord blood HSC (p < 0.0001), and adult bone marrow HSC (p = 1343 
0.0076) 1344 
 1345 
Extended Data 1g displays flow cytometric analysis of the frequency of B cells in the CD34- 1346 
cells from n = 13 6-9 PCW, n = 13 9-12 PCW, n = 14 12-15 PCW and n = 9 15-19 PCW 1347 
biologically independent fetal liver samples. Statistical significance across the developmental 1348 
stages was compared using Kruskal-Wallis with Dunn’s multiple comparison post-test, for 1349 
which the following comparisons were statistically significant: 6-9 PCW vs 12-15 PCW (p < 1350 
0.0001), 6-9 PCW vs 15-19 PCW (p = 0.0003), 9-12 PCW vs 12-15 PCW (p = 0.0157), and 1351 
9-12 PCW vs 15-19 PCW (p = 0.0287). 1352 
 1353 
Statistically significant, dynamically variable genes from pseudotime were determined by 1354 
Likelihood of ratio test applied in monocle (see Methods). Select genes were displayed for 1355 
Erythroid, Mast cell and Megakaryocyte lineages shown in Extended Data 3b, B cell lineage 1356 
shown in Extended Data 5e, and DC1, DC2 and Monocyte lineage shown in Extended Data 1357 
6b. 1358 
 1359 
Investigation of potential receptor:ligand interactions between all fetal liver VCAM1+ EI 1360 
macrophages (161 cells) and Early and Mid Erythroids (11,985 and 27,000 cells 1361 
respectively), as shown in Extended Data 4a, was performed using CellPhoneDB (see 1362 
Methods). A permutation test was applied to determine statistical significance, which is 1363 
indicated by the colour of the dots. ln-normalised median expression of ITGA4 and VCAM1 1364 
in the same cells is also displayed in a violin plot (right panel). 1365 
 1366 
ImageStream analysis of fetal liver cells shown in Extended Data 4c-f was performed on n = 1367 
3 biologically independent samples. Extended Data 4c-d display representative data from one 1368 
sample.  Extended Data 4e shows representative images of cells from 38,576 single cells and 1369 
1,945 doublets from one sample.  The percent of each cell type that was observed within the 1370 
doublet of singlet gate, as per Extended Data 4c, was compared using Kruskal-Wallis with 1371 
Dunn’s post hoc test. The percent of doublets in VCAM1+ EI macrophages was significantly 1372 
different the percent of doublets in Erythroids (p = 0.0194). 1373 
 1374 
Statistical significance of TNFSF13B expression in Kupffer cells over time compared to 1375 
NFKBIA in HSC/MPPs (p = 0.0245), Pre pro B cells (p = 0.0008), Pro B cells (p = 0.0004), 1376 
42 
Pre B cells (p = 0.0197) and B cells (p = 0.0343) across 4 developmental stages spanning 6-1377 
17 PCW was determined using two-tailed Pearson’s R test.  1378 
 1379 
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